I spent a lot of years building genetics programs in California, Oregon, and Colorado before I came to Maryland. The West Coast got a head start on almost everything: genetics, extraction, product development, and, frankly, figuring out what consumers actually want once they get past shopping by THC percentage.
It also made plenty of mistakes. Maryland gets to learn from both.
RELATED: Cannabis has a workforce problem. Minnesota may have the answer
Something worth understanding about West Coast genetics programs is that they’re mostly driven by yield and menu gaps. When the price per pound is low, the hunt is for high-yielding plants for extraction, high grams per square foot for indoor, fast-finishing sativas to plug a hole in the menu, and new hybrids with “searchable” names that do well when somebody types them into a menu. That’s the pressure those programs live under, and it shapes what gets bred and what gets kept.
On the East Coast, the price per pound is significantly higher, which relieves some of that yield pressure. Here it falls into a different bucket: potency. Nine out of ten decisions at retail in Maryland come down to some version of “how potent is it?” People walk into a dispensary and ask for the highest THC number on the shelf. I’ve never fully understood that instinct. You don’t ask a bartender for the strongest pour before you order.
But it’s starting to change. People are asking about genetics and how products are made. They’re coming back from California or Colorado wanting to know why they can’t find the same things here. They know the difference between distillate and rosin. They’re curious about cannabinoids beyond THC.
That’s the shift I pay attention to, and concentrates are where it shows up first. Maryland’s concentrate category is still underdeveloped compared to the West, where most of the industry’s R&D on solventless extraction has happened.
RELATED: Cannabis investors stay on sidelines despite rescheduling momentum
Here’s the hard part. In theory, potency would correlate directly with extraction yield, if all solvents were created equal. They aren’t. A cultivar can hit potency specs as dry flower and look great in the room, then fall apart in an ice water wash. Finding genetics that win on both sides, as flower and in solventless, takes a long time and a lot of frustrating failures. That timeline turns most companies away from doing real R&D at all. It’s easier to buy whatever’s available and put a label on it.
Doing solventless right starts six to nine months before there’s anything to sell. The material has to come from genetics selected with washing in mind, not just genetics that happen to grow well, so the decision gets made at the garden level. That’s the standard we set for East West, our live rosin line, and I think it’s the baseline Maryland’s concentrate category needs if it wants to earn West Coast comparisons rather than borrow them.
Solventless also rewards keeping cultivation and extraction close together. Frozen material doesn’t tolerate handling. Every time it changes hands or moves between facilities, there’s a chance it warms up even slightly and loses quality. When the same team grows and washes, it can work a problem from both directions, tracing a batch that isn’t washing well back to how it was grown instead of guessing at the extraction.
Hardware is the next gap. Nearly every standard vape cartridge on the market was built around distillate’s properties, and rosin behaves nothing like distillate. It’s thicker, stickier, and harder on equipment that wasn’t designed for it. As more of the category moves solventless into vapes, the hardware has to catch up, with options like all-glass cartridges and ceramic atomizers that handle thicker material without dulling the flavor. If the genetics and the extraction are supposed to be the stars, the hardware has to stay out of the way.
This is where Maryland has a real advantage. We can take years of R&D from mature markets and apply it here without learning every lesson the hard way.
But the West Coast also shows you what happens on the other side of that curve.
RELATED: Cannabis consumers want more than just “good weed”
I’ve watched the saturated markets out there get forced into compromise by overproduction. When everyone is sitting on more product than the market can absorb, price becomes the only strategic lever anyone has left to gain share. So product quality slides, the human touchpoints get stripped out of the experience, and the one place spending goes up is packaging, which gets more expensive and generates more trash every year. You end up buying a stick of bubblegum in an iPhone box.
The limited-license markets have been victims of the other side of that same coin. Companies that lost enormous sums chasing market share in the big West Coast population centers are doing everything they can to recoup those losses in states where the license count is capped. Consumers in those markets haven’t had the same exposure to great product, and more to the point, they have far fewer competitive options. The result is predictable: no innovation, no pressure on quality, and high prices.
Neither of those is the market I want to build in.
What we want to do is carry the learned behavior over. The consumer pressure. The relentless demand for the highest quality at the fairest price. We want to bring that into a market where those demands don’t exist yet, and hold ourselves to it before anyone here asks us to. The West Coast mentality, without the panic-driven pricing and the greed-driven overproduction, dropped into a complacent East Coast market.
That means pushing ourselves, and pushing our peers, to make the best possible product. If we do that, Maryland over the next hundred years becomes synonymous with great cannabis, stewarded by people who actually care about it.
*This article was submitted by an unpaid guest contributor. The opinions or statements within do not necessarily reflect those of GreenState or HNP. The author is solely responsible for the content.